Ray Kaczmarek joins Genezen with over 20 years of experience in operations management within the pharmaceutical and biotech industries. His proven leadership in strategic manufacturing management, for both clinical and commercial manufacturing, makes him perfectly suited to contribute to the future success of the company.
Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector invests in Genezen.
Expansion of our process development lab begins. Due to complete in Fall 2021, the lab is the first part of our new 25,000 square foot cGMP-compliant lentiviral vector production facility which will also offer a full suite of analytical capabilities, ready in early 2022.
It’s the first phase of a broader master plan for a 75,000+ square foot facility.
Creating nearly 100 high-wage jobs, we announced plans to open a research and development lab and clean manufacturing facility with office space in the Crosspoint Business Park in the growing life-science hub Fishers, IN.
Following an incredible revenue growth from 2017 to 2019 of 424%, the Indiana Business Journal has named Genezen Laboratories the fastest growing company in central Indiana.
The laboratory excels in cell manufacturing for clinical trials. The partnership initially enabled the production of GMP grade retroviral and lentiviral vectors with quality control testing including vector titer by functional assay FACS or PCR, mycoplasma, and sterility testing.
Genezen set out to connect academia and pharma and began working closely with Dr. Ken Cornetta at Indiana University, who has more than 25 years of experience in viral vector production and testing. His vision of making vector production readily available informs our work today. As our clients’ needs grew, we added the expertise of Indiana University, a pioneer in many therapies with who we still partner today to expand our clinical trial sample testing capabilities.